Skip to main content

Deloitte China assists the listing of Lung Fung Group on SEHK

Deloitte China supported the listing of Lung Fung Group Holdings (“Lung Fung Group”, stock code: 02290.HK) on the Stock Exchange of Hong Kong (SEHK) on 5 June 2026.

In this global offering, Lung Fung Group offered 125 million shares at HKD5.18 each, raising approximately HKD647.5 million.

the listing ceremony of Nsing Technologies at Hong Kong Stock Exchange
the listing ceremony of Nsing Technologies at Hong Kong Stock Exchange

(from left) Derek Chung, CFO of Lung Fung Group; Athena Tsui, manager and Krates Chan, partner, Audit & Assurance (A&A), Deloitte China; Polly Lee, Deputy National managing partner and managing partner of Southern Region of A&A, Deloitte China; Tse Siu Hoi, executive director and chairman of the Board of Lung Fung Group; Anthony Tsang and Thomas Chan, A&A partners; Grace Luo, A&A associate director; Picken Wan, A&A senior manager and Joseph Chow, A&A manager of Deloitte China, attend the listing ceremony of Lung Fung Group at Hong Kong Stock Exchange.

Client overview

Lung Fung Group is a Hong Kong-based chain retail store of beauty, health and pharmaceutical products which operates 31 retail stores and various online sales channels under the brand of Lung Fung.

Lung Fung Group offers a wide variety of beauty products, health products, pharmaceutical products and other consumer goods such as household and daily essentials and food products, covering 11 categories, namely proprietary Chinese medicines, western medicines, health supplements, skincare, cosmetics, fragrances, personal care, maternal and infant products, food, pet food and household daily necessities.

According to Frost & Sullivan, in the financial year of 2025, Lung Fung Group ranked 3rd among beauty, health and pharmaceutical product retailers with a market share of 5.8% in terms of retail sales value in Hong Kong. Lung Fung Group was also the largest pharmaceutical product retailer by retail sales value in Hong Kong, with a market share of 5.2%, and the 3rd largest pharmaceutical and health product retailer by revenue in Hong Kong, with a market share of approximately 4.2%.

Deloitte's role

The listing of Lung Fung Group spanned industry cycles, bearing witness to the resilience of the company and Deloitte's service teams. As a core service institution of this new listing engagement, Deloitte China was deeply involved in the entire process of the IPO. This successful listing demonstrates Deloitte’s rich professional expertise and capital market service capabilities. The engagement team worked closely with various professional parties and provided high-quality services with rich industry experience and excellent professional capabilities to assist Lung Fung Group to list on the Main Board of the SEHK.

Deloitte China congratulates Lung Fung Group on its successful listing on the SEHK. We will continue to provide high-quality professional services and outstanding resource integration to assist more clients to take one-step ahead in today's increasingly competitive and complex business environment.